YF-S0- A Potential Candidate For COVID-19

A study published in the journal Nature described a safe and effective live-attenuated yellow fever 17D (YF17D) vector-based vaccine candidate expressing the spike protein of SARS-CoV-2. The vaccine candidate is named YF-S0. YF1D viral vector has been previously used for the development of vaccines for Japanese encephalitis and dengue. Using reverse genetics, a set of YF17D-based vaccine candidates expressing the SARS-CoV-2 spike protein in multiple forms including the native cleavable form (YF-S1/2), fusion form (YF-S1), and non-cleavable form (YF-S0).

Hamsters were vaccinated on day 0 and day 21. After 21 days of vaccination, YF-S0 had the highest potency to generate SARS-CoV-2-specific IgG neutralizing antibodies. Similar effects were observed in non-human primates. An experimental mouse model was used to determine the abilities of vaccine candidates in inducing T cell-mediated immune responses. WBC population from the spleen of the vaccinated mice were analyzed and it was observed that all the vaccine candidates were capable of inducing spike protein-specific  T cell responses with a satisfactory T helper type 1 (Th1) polarization.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://www.nature.com/articles/s41586-020-3035-9